Prognostic factors in chronic lymphocytic leukemia

Annals of Oncology

Volumn 19, Issue SUPPL. 4, 2008, Pages

  Hallek, M ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALKYLATING AGENT; BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; CD23 ANTIGEN; CD38 ANTIGEN; IMMUNOGLOBULIN HEAVY CHAIN; PROTEIN KINASE ZAP 70; PURINE DERIVATIVE; THYMIDINE KINASE;

ARTICLE; BONE MARROW EXAMINATION; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME TRANSLOCATION; CHRONIC LYMPHATIC LEUKEMIA; CYTOGENETICS; DISEASE COURSE; DRUG RESPONSE; GENE DELETION; GENE EXPRESSION; GENE MUTATION; HUMAN; IMMUNOGLOBULIN VARIABLE REGION; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MOLECULAR GENETICS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; B CELL LEUKEMIA; METHODOLOGY; MOLECULAR BIOLOGY; PATHOLOGY; PRACTICE GUIDELINE; REVIEW;

BIOLOGICAL MARKERS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MOLECULAR BIOLOGY; NEOPLASM STAGING; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS;

EID: 48149088333     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn196     Document Type: Article

References (39)

1. Hallek M, Cheson BD, Catovsky D et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer Institute Working Group (NCI-WG) 1996 guidelines. Blood 2008.
2. Rai KR, Sawitsky A, Cronkite EP et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219-234.
3. Binet JL, Auquier A, Dighiero G et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981; 48: 198-204.
4. Rai KR. A critical analysis of staging in CLL. In Gale RP, Rai KR (eds): Chronic Lymphocytic Leukemia: Recent Progress and Future Directions. New York: Alan R. Liss 1987; 253-264.
5. Döhner H, Stilgenbauer S, Benner A et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910-1916.
6. Mayr C, Speicher MR, Kofler DM et al. Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. Blood 2006; 107: 742-751.
7. Haferlach C, Dicker F, Schnittger S et al. Comprehensive genetic characterization of CLL: A study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping. Leukemia 2007; 21: 2442-2451.
8. Döhner H, Fischer K, Bentz M et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995; 85: 1580-1589.
9. Graver MR, Lucas DM, Dewald GW et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: Results from the US Intergroup Phase III Trial E2997. J Clin Oncol 2007; 25: 799-804.
10. Stilgenbauer S, Dohner H. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N Engl J Med 2002; 347: 452-453.
11. Lozanski G, Heerema NA, Flinn IW et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004; 103: 3278-3281.
12. Shanafelt TD, Witzig TE, Fink SR et al. Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol 2006; 24: 4634-4641.
13. Damle RN, Wasil T, Fais F et al. IgV gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840-1847.
14. Hamblin TJ, Davis Z, Gardiner A et al. Unmutated IgV(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848-1854.
15. Thorselius M, Krober A, Murray F et al. Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational status. Blood 2006; 107: 2889-2894.
16. Orchard A Ibbotson RE, Davis Z et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 2004; 363: 105-111.
17. Crespo M, Bosch F, Villamor N et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003; 348: 1764-1775.
18. Rassenti LZ, Huynh L, Toy TL et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004; 351: 893-901.
19. Ibrahim S, Keating M, Do KA et al. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood 2001; 98: 181-186.
20. Lin K, Sherrington PD, Dennis M et al. Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia. Blood 2002; 100: 1404-1409.
21. Ghia P, Guida G, Stella S et al. The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood 2003; 101: 1262-1269.
22. Boonstra JG, van Lom K, Langerak AW et al. CD38 as a prognostic factor in B cell chronic lymphocytic leukaemia. (B-CLL): Comparison of three approaches to analyze its expression. Cytometry B Clin Cytom 2006; 70: 136-141.
23. Byrd JC, Gribben JG, Peterson BL et al. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: Justification for risk-adapted therapy. J Clin Oncol 2006; 24: 437-443.
24. Hallek M, Langenmayer I, Nerl C et al. Elevated serum thymidine kinase levels identify a subgroup at high risk of disease-progression in early, non-smoldering chronic lymphocytic leukemia. Blood 1999; 93: 1732-1737.
25. Keating MJ, Lerner S, Kantarjian H et al. The serum β2-microglobulin (β2m) level is more powerful than stage in predicting response and survival in chronic lymphocytic leukemia (CLL). Blood 1995; 86 (Suppl. 1): 606a.
26. Reinisch W, Willheim M, Hilgarth M et al. Soluble CD23 reliably reflects disease activity in B-cell chronic lymphocytic leukemia. J Clin Oncol 1994; 12: 2146-2149.
27. Sarfati M, Chevret S, Chastang C et al. Prognostic importance of serum soluble CD23 level in chronic lymphocytic leukemia. Blood 1996; 88: 4259-4264.
28. Wierda WG, O'Brien S, Wang X et al. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood 2007; 109: 4679-4685.
29. Magnac C, Porcher R, Davi F et al. Predictive value of serum thymidine kinase level for Ig-V mutational status in B-CLL. Leukemia 2003; 17: 133-137.
30. Matthews C, Catherwood MA, Morris TC et al. Serum TK levels in CLL identify Binet stage A patients within biologically defined prognostic subgroups most likely to undergo disease progression. Eur J Haematol 2006; 77: 309-317.
31. Bergmann MA, Eichhorst BF, Busch R et al. Prospective evaluation of prognostic parameters in early stage chronic lymphocytic leukemia (CLL): Results of the CLL1)-protocol of the German CLL Study Group (GCLLSG). ASH Annual Meeting Abstracts 2007; 110: 625.
32. Galton DAG. The pathogenesis of chronic lymphocytic leukemia. Can Med Assoc J 1966; 94: 1005-1010.
33. Montserrat E, Sanchez BJ, Vinolas N et al. Lymphocyte doubling time in chronic lymphocytic leukaemia: Analysis of its prognostic significance. Br J Haematol 1986; 62: 567-575.
34. Molica S, Alberti A. Prognostic value of lymphocyte doubling time in chronic lymphocytic leukemia. Cancer 1987; 60: 2712-2716.
35. Vallespi T, Montserrat E, Sanz MA. Chronic lymphocytic leukaemia: prognostic value of lymphocyte morphological subtypes. A multivariate survival analysis in 146 patients. Br J Haematol 1991; 77: 478-485.
36. Dhodapkar M, Tefferi A, Su J et al. Prognostic features and survival in young adults with early/intermediate chronic lymphocytic leukemia (B-CLL): A single institution study. Leukemia 1993; 7: 1232-1235.
37. Molica S, Reverter JC, Alberti A et al. Timing of diagnosis and lymphocyte accumulation patterns in chronic lymphocytic leukemia: analysis of their clinical significance. Eur J Haematol 1990; 44: 277-281.
38. Langenmayer I, Nerl C, Knauf W et al. Interferon alpha 2b in the treatment of early stage CLL with risk for progression. Results of a randomized multicenter study. Br J Haematol 1996; 94: 362-369.
39. Montserrat E, Rozman C. Chronic lymphocytic leukaemia: Prognostic factors and natural history. Baillieres Clin Haematol 1993; 6: 849-866.